$NTHIOct 7, 2026, 9:59 AM ETAI processed
NTHI’s intranasal NEO100 Phase 2a shows 26.1‑month median OS in recurrent high‑grade glioma; highlighted among five 2026 cancer advances
AI Summary
A market roundup highlighted five oncology advances in 2026 and flagged NeOnc (NTHI) after its 24‑patient Phase 2a of intranasal NEO100 reported a median overall survival of 26.09 months from the first post‑recurrence dose, with mostly low‑grade adverse events and at‑home dosing that bypasses the blood‑brain barrier. The result is an encouraging survival signal in recurrent Grade III/IV IDH1‑mutant glioma but is non‑randomized with no concurrent control and mixed progression‑free survival findings; NeOnc plans FDA discussions on a registrational pathway and has a separate Nov. 17, 2026 EOP1 meeting for its NEO212 program.
Positives
- Phase 2a (n=24) reported median overall survival 26.09 months measured from first treatment after recurrence
- Mostly low‑grade adverse events and no major toxicities reported; intranasal at‑home dosing designed to bypass the blood‑brain barrier
- Company plans to discuss registrational pathway with FDA and has a separate EOP1 meeting for NEO212 on Nov 17, 2026
Negatives
- Study was non‑randomized with no concurrent control group, so survival is an encouraging signal not proof of benefit
- Progression‑free survival results were mixed: significant against a historical RANO 2.0 benchmark but not under the original protocol criteria
- Small sample size (24 patients) and narrow population (recurrent/progressive Grade III–IV IDH1‑mutant glioma) limits generalizability